- Home
- LPRO vs FHTX Comparison
LPRO vs FHTX Comparison
Compare LPRO & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | FHTX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 247.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPRO | FHTX |
|---|---|---|
| Price | $1.52 | $5.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $2.83 | ★ $11.43 |
| AVG Volume (30 Days) | ★ 578.1K | 158.8K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $16,948,000.00 | ★ $24,518,000.00 |
| Revenue This Year | $306.66 | $40.89 |
| Revenue Next Year | $7.97 | $11.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $2.95 |
| 52 Week High | $6.73 | $6.79 |
Technical Indicators
Market Signals| Indicator | LPRO | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.35 | 56.33 |
| Support Level | $1.56 | $5.01 |
| Resistance Level | $1.68 | $5.54 |
| Average True Range (ATR) | 0.09 | 0.35 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 4.05 | 58.62 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.